Cancer Care and COVID-19

Dr. Lisa C. Richardson, MD, Director of the Centers for Disease Control and Prevention’s (CDC) Division of Cancer Prevention and Control (DCPC), discusses what cancer patients and their caregivers need to know to stay well while staying at home during the COVID-19 crisis and what to do should anyone with cancer or caring for someone with cancer contract COVID-19.

Read More

Caris Life Sciences® – whole exome sequencing

Dr. David Spetzler, President and Chief Scientific Officer at Caris Life Sciences® discusses MI Exome™ a next-generation sequencing-based assay analyzing the whole exome of 22,000 DNA genes. This new assay will be offered as part of the Caris Molecular Intelligence® suite of comprehensive profiling services that are designed to detect and characterize the molecular features of cancer to guide more precise individualized treatment decisions for patients.

Read More

eClinicalWorks® healow Telehealth Solutions

Rakhee Langer, Vice President, healow telehealth solutions at eClinicalWorks®, a leader in healthcare IT solutions, discusses the healow telehealth platform features and capabilities that are contributing to better decision making and patient care.  She talks about the importance of telehealth during the COVID-19 pandemic, social distancing, and beyond.  Healow logged more than 10 million minutes in the first 10 days of April 2020.

Read More

Special Olympics COVID-19 advice for those with Intellectual disabilities

Dr. Alicia Bazzano, Chief Health Officer for Special Olympics, discusses the resources they have added to their website in response to the COVID-19 pandemic providing critical information to their athletes, caregivers, and loved ones of individuals with intellectual disabilities (ID).  She also talks about the “School of Strength” a fitness campaign in partnership with WWE to help athletes stay active.

Read More

Phase l Study – Boltbody™ Immune-Stimulating Antibody Conjugates (ISAC)

Dr. Randy Schatzman, CEO at Bolt Biotherapeutics, Inc., discusses how Bolt is developing drugs to turn cold tumors “hot” to achieve an anti-tumoral activity in unresponsive patients.  They are ahead of their competitors as they have already started the Phase 1 study of BDC-1001 monotherapy for patients with HER2-expressed solid tumors.  He discusses how they are using the Boltbody™ Immune-Stimulating Antibody Conjugates (ISAC) approach to combat cancer and how this technology is shaping the treatment of cancers.

Read More